Press Release: Mobidiag Presents Two New Diagnostic Platforms at ECCMID 2015

Novodiag™ and Amplidiag™ Easy platforms to serve both low- and high-throughput customer needs with emphasis on accessibility and affordability

Espoo, Finland – April 22, 2015 – Mobidiag Ltd, a Finnish molecular diagnostics company specializing in the development of innovative diagnostics solutions for infectious diseases, today announced the first public presentation of two new diagnostic platforms – Novodiag and Amplidiag Easy – at ECCMID 2015 in Copenhagen on April 25-28.

The entirely new Novodiag platform is a fully integrated and automated system, enabling accessible and affordable molecular testing. The platform enables fast, very easy to use and highly multiplexed on-demand molecular testing for any throughput needs. It combines advanced features, ease of use, and affordability unmatched by currently available products, and requires no dedicated molecular testing expertise. The Novodiag platform will be readied for a full commercial launch in mid-2016 to serve various testing needs in the infectious diseases space, as well as in other potential markets which are unserved by current molecular platforms.

“Although molecular diagnostics has been around for a long time, the market has not seen solutions which leverage its full potential,” says Tuomas Tenkanen, CEO of Mobidiag. “Until now, major limitations have been complexity of use, the ability to detect only a very limited amount of pathogens, or simply too high a price. We aim to solve these issues with our Novodiag system by combining high multiplexing capacity with a simplified, easy-to-use design. The system and its benefits will be accessible to a broader group of diagnostic laboratories, both centralized and decentralized. Due to its simplified design, it represents industry-leading value, setting a new benchmark for affordability and functionality.”

Mobidiag is also launching its new Amplidiag Easy system for automating high-throughput gastrointestinal testing with Amplidiag test kits, including the recently CE-marked Amplidiag Bacterial GE and Amplidiag C. difficile+027. The system performs batch nucleic acid extraction and PCR plate setup from stool samples with unmatched speed and performance. Combined with Amplidiag test kits and Amplidiag Analyzer software for automatic result analysis, the platform provides ease of use and uncompromised reliability in high-throughput molecular testing.

“We value the feedback of our customers, and it is clear that in many high-throughput laboratories, automated systems are not only appreciated for reducing the burden of tight resources, but the only way of working,” Mr. Tenkanen continues. “That’s why we created Amplidiag Easy specifically to meet this need, combining automation with speed and reliability. For example, the system can process a batch of 48 C. difficile samples in one hour, from a liquid stool sample transfer vial ending up in a ready set-up PCR plate to be transferred to a qPCR instrument. In an optimized workflow, the results are available for a large batch of samples in two hours from sample to result. The best thing is that the high speed does not compromise performance at all.”

About Mobidiag

Established in 2000, Mobidiag develops novel technologies for improving the diagnostics of infectious diseases and has served the European clinical diagnostics market with its multiplex Prove-it™ product family since 2008. In 2013, Mobidiag successfully completed a three-way merger with Genewave and Amplidiag, solidifying its position in the field of molecular diagnostics. Mobidiag’s new Amplidiag™ product line encompasses innovative multiplex diagnostic tests for gastrointestinal infections. The products use well-established qPCR technology, ensuring optimal performance, suitability for high-volume screening use and cost-effectiveness in mid-sized to large laboratory settings. Mobidiag’s new Novodiag™ platform will set a new benchmark to automated, integrated molecular diagnostics. Mobidiag is headquartered in Espoo, Finland, with a subsidiary in Paris, France.


Mobidiag Oy/Ltd.
Tuomas Tenkanen, CEO
+350 50 553 4980